Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a
company focused on developing, marketing and selling a variety of
men’s health and wellness products via a secure telemedicine
platform, including its uniquely formulated erectile dysfunction
(ED) drug branded “Mango,” is pleased to announce that it has added
serial technology entrepreneur and investor, Aaron Andrew, to its
advisory board (the “Advisory Board”).
On January 5, 2023, the Company established the
Advisory Board and approved and adopted a charter (the “Advisory
Board Charter”) to govern the Advisory Board. Pursuant to the
Advisory Board Charter, the primary function of the Advisory Board
is to assist the Board of Directors in its general oversight of the
Company’s development of new business ventures and strategic
planning.
Mr. Andrew will assist the Company with
providing his guidance and expertise as it relates to both curating
content designed for influencer and affiliate marketing, in
addition to making key introductions to his vast influencer network
across the United States. He represents the third addition to the
Company’s Advisory Board. Other members include Dr. Brian Rudman,
founder of Dallas-based wellness clinic chain, Formula Wellness,
and Jarrett Boon, an original thought-leader and investor involved
in LifeLock, Inc.
Below are brief bios on each of the Company’s
current Advisory Board members:
Aaron Andrew.
Aaron Andrew is a serial technology entrepreneur and
investor. A social media visionary, Mr. Andrew is responsible
for starting and running one of the largest creator networks in the
world with a global reach of 85+ million people. He launched and
currently operates the largest Snapchat discovery app, and the
largest link landing page app. Mr. Andrew has run targeted
marketing campaigns for several Fortune 500 companies and leading
technology start-ups. In addition, Mr. Andrew is also a prolific
start-up investor and serves on the board of several private
companies including Ceartas DMCA, Next Health, and Edge Payments
where he provides invaluable insights and guidance on achieving
growth through social media and influencer marketing campaigns.
Through his various companies, Mr. Andrew has significant expertise
in Internet Technologies, Web Design/Development, Digital Media
Marketing, and Copyright & Brand Protection.
Jarrett Boon.
Mr. Boon has over 30 years of experience in building successful
businesses from creation to exit. He was one of the original
thought leaders and investors in LifeLock where he applied his
expertise in sales, marketing, and strategic business development,
to grow LifeLock to $500M in revenue. LifeLock went public in
October 2012 and was subsequently acquired by Symantec in November
2016 for $2.3B. Prior to LifeLock, Mr. Boon founded SW
Promotions, Inc, a resort marketing, and advertising company. SW
Promotions and its 400 employees were acquired by one of its
publicly traded partners.
Dr. Brian Rudman,
M.D. A passionate doctor with over 20 years of experience.
Dr. Rudman has taken his experience with the medical and surgical
problems that patients face into a new role that focuses on
preventing illness and preserving wellness. He has seen
excellent doctors make incredible advances in treating diseases
with surgery and medicine that were unimaginable 20 years ago;
however, our environment continues to challenge our bodies
making it more and more difficult for us to fight the negative
effects of aging and our environment. Dr. Rudman has joined the
growing fight with numerous other physicians to focus on balancing
the western medical approach to disease with a heavy
concentration on the preservation of wellness and the
prevention of illness. As a board-certified Anesthesiologist since
1997, Dr. Rudman has had the pleasure of treating thousands of
patients across every age group. He has seen first-hand the
consequences and side effects of conventional medical treatment as
well as the implications on the ultimate surgical management of
disease processes. Throughout his career he has witnessed the
progressive increase in obesity and related diseases that have
become the result of the modern-day environment in which we
live.
Dr. Rudman attended Northwestern University in
Evanston, Illinois for his undergraduate training. There he
completed his pre-medical studies while obtaining a Bachelor of
Arts in History. He then continued to the University of
Missouri securing his Doctorate in Medicine before going back to
Northwestern University for an advanced residency training in
Anesthesiology. While at Northwestern, Dr. Rudman
proudly served as Chief Resident during his final
year. After 20 years of leading several successful
medical practices, he began to devote his attention toward the
board certification process and is now Board Certified in
Anti-Aging and Regenerative Medicine with the American Academy
of Anti-Aging Medicine (A4M).
About Mango
Created using a special formulation featuring
the same active ingredient as in Cialis (Tadalafil), each part of
the Mango formulation plays a critical role in helping men achieve
optimum performance. We believe the key to our success lies in our
unique blend of ingredients, which are used in U.S. Food and Drug
Administration (“FDA”) approved drugs. Mango contains a combination
of Tadalafil, Oxytocin, and L-Arginine that have been traditionally
used to treat sexual dysfunction.
Mango is a prescription medication that must be
approved by a physician. After an individual has completed an
online telehealth visit, our network of medical providers will
review and approve a prescription if medically appropriate. Mango
is a rapidly dissolved tablet (RDT) that is absorbed orally. For
best results, we advise taking Mango at least 15 minutes before
engaging in sexual activity. Tadalafil, one of the main ingredients
in Mango, typically has effects that last up to 36 hours.
About Mangoceuticals
Mangoceuticals, Inc. is a company focused on
developing, marketing, and selling a variety of men's health and
wellness products and services via a secure telemedicine platform.
To date, the Company has identified men's wellness telemedicine
services and products as a growing sector and especially related to
the area of erectile dysfunction (ED). The Company has developed a
new brand of ED product under the brand name "Mango" (think "Man
Go"). For more information, please visit www.MangoRx.com.
Cautionary Note Regarding
Forward-Looking Statements
Certain statements made in this press release
contain forward-looking information within the meaning of
applicable securities laws, including within the meaning of the
Private Securities Litigation Reform Act of 1995 ("forward-looking
statements"). These forward-looking statements represent the
Company's current expectations or beliefs concerning future events
and can generally be identified using statements that include words
such as "estimate," "expects," "project," "believe," "anticipate,"
"intend," "plan," "foresee," "forecast," "likely," "will," "target"
or similar words or phrases. These forward-looking statements are
subject to risks, uncertainties and other factors, many of which
are outside of the Company's control which could cause actual
results to differ materially from the results expressed or implied
in the forward-looking statements, including, but not limited to;
our ability to obtain additional funding and generate revenues to
support our operations; risks associated with our ED product which
have not been, and will not be, approved by the U.S. Food and Drug
Administration ("FDA") and have not had the benefit of the FDA's
clinical trial protocol which seeks to prevent the possibility of
serious patient injury and death; risks that the FDA may determine
that the compounding of our planned products does not fall within
the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA
Act") provided by Section 503A; risks associated with related party
relationships and agreements; the effect of data security breaches,
malicious code and/or hackers; competition and our ability to
create a well-known brand name; changes in consumer tastes and
preferences; material changes and/or terminations of our
relationships with key parties; significant product returns from
customers, product liability, recalls and litigation associated
with tainted products or products found to cause health issues; our
ability to innovate, expand our offerings and compete against
competitors which may have greater resources; our significant
reliance on related party transactions; the projected size of the
potential market for our technologies and products; risks related
to the fact that our Chairman and Chief Executive Officer, Jacob D.
Cohen, has majority voting control over the Company; risks related
to the significant number of shares in the public float, our share
volume, the effect of sales of a significant number of shares in
the marketplace, and the fact that the majority of our shareholders
paid less for their shares than the public offering price of our
common stock in our recent initial public offering; the fact that
we have a significant number of outstanding warrants to purchase
shares of common stock at $1.00 per share, the resale of which
underlying shares have been registered under the Securities Act of
1933, as amended; our ability to build and maintain our brand;
cybersecurity, information systems and fraud risks and problems
with our websites; changes in, and our compliance with, rules and
regulations affecting our operations, sales, marketing and/or our
products; shipping, production or manufacturing delays; regulations
we are required to comply with in connection with our operations,
manufacturing, labeling and shipping; our dependency on
third-parties to prescribe and compound our ED product; our ability
to establish or maintain relations and/or relationships with
third-parties; potential safety risks associated with our Mango ED
product, including the use of ingredients, combination of such
ingredients and the dosages thereof; the effects of high inflation,
increasing interest rates and economic downturns, including
potential recessions, as well as macroeconomic, geopolitical,
health and industry trends, pandemics, acts of war (including the
ongoing Ukraine/Russian conflict) and other large-scale crises; our
ability to protect intellectual property rights; our ability to
attract and retain key personnel to manage our business
effectively; our ability to maintain the listing of our common
stock on the Nasdaq Capital Market; overhang which may reduce the
value of our common stock; volatility in the trading price of our
common stock; and general consumer sentiment and economic
conditions that may affect levels of discretionary customer
purchases of the Company's products, including potential recessions
and global economic slowdowns. Although we believe that our plans,
intentions and expectations reflected in or suggested by the
forward-looking statements we make in this release are reasonable,
we provide no assurance that these plans, intentions or
expectations will be achieved. Consequently, you should not
consider any such list to be a complete set of all potential risks
and uncertainties. More information on potential factors that could
affect the Company's financial results is included from time to
time in the "Cautionary Note Regarding Forward-Looking Statements,"
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" sections of the
Company's filings with the SEC, including the Company’s Quarterly
Report on Form 10-Q for the Quarter ended March 31, 2023. These
filings are available at www.sec.gov and at our website at
https://investors.mangorx.com/sec-filings. All subsequent written
and oral forward-looking statements attributable to the Company or
any person acting on behalf of the Company are expressly qualified
in their entirety by the cautionary statements referenced above.
Other unknown or unpredictable factors also could have material
adverse effects on the Company's future results. The
forward-looking statements included in this press release are made
only as of the date hereof. The Company cannot guarantee future
results, levels of activity, performance or achievements.
Accordingly, you should not place undue reliance on these
forward-looking statements. Finally, the Company undertakes no
obligation to update these statements after the date of this
release, except as required by law, and takes no obligation to
update or correct information prepared by third parties that are
not paid for by the Company. If we update one or more
forward-looking statements, no inference should be drawn that we
will make additional updates with respect to those or other
forward-looking statements.
FOR INVESTOR RELATIONS
Fraxon Market Initiatives, LLC Frank Benedetto Phone:
619-915-9422 Email: https://www.mangoceuticals.com MEDIA
CONTACT
Phoenix MGMT Marketing & Consulting
info@phoenix-mediamarketing.com
SOURCE: Mangoceuticals Inc.
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mangoceuticals (NASDAQ:MGRX)
Historical Stock Chart
From Sep 2023 to Sep 2024